Lynne Mofenson, M.D., Joins Elizabeth Glaser Pediatric AIDS Foundation Research Team
FOR IMMEDIATE RELEASE
Media Contacts: Johanna Harvey: firstname.lastname@example.org or +1 (202) 280-1657
Washington, D.C.—Nov. 10, 2014—The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) is pleased to welcome acclaimed pediatrician and pediatric AIDS specialist Lynne Mofenson, M.D., to its research team. In her new role as senior HIV technical advisor, Dr. Mofenson will leverage her vast knowledge as a leading HIV/AIDS researcher to further EGPAF’s mission to end AIDS in children worldwide.
“Dr. Mofenson has been at the forefront of AIDS research since the very beginning of the epidemic. She brings more than two and a half decades of experience in pediatric AIDS treatment and prevention,” said Laura Guay, M.D., vice president of research at EGPAF. “Her global research and policy expertise will be invaluable to EGPAF as we work in thousands of health care sites around the world to conduct research and implement programs to end pediatric AIDS.”
Dr. Mofenson will support EGPAF’s role in the five-year, U.S. Agency for International Development (USAID)-funded Supporting Operational AIDS Research (SOAR) project. Led by the Population Council, EGPAF is part of a consortium of leading organizations conducting operational HIV and AIDS research to determine how best to address challenges and gaps that remain in the delivery of HIV and AIDS care and support, treatment, and prevention services.
“I am honored to join EGPAF’s prestigious team of researchers, advocates, and global HIV/AIDS experts,” said Dr. Mofenson. “EGPAF began as an organization focused on supporting much-needed pediatric AIDS research and the work it does today continues to change the future for children, families, and countries most severely impacted by the AIDS epidemic. I look forward to being a part of EGPAF as we work to create an AIDS-free generation.”
Prior to joining EGPAF, Dr. Mofenson spent 25 years at the National Institute of Child Health and Human Development (NICHD), where she was responsible for establishing and conducting clinical trials in prevention, treatment and management of HIV infection in infants, children, adolescents, and women – both domestically and internationally. Her accomplishments include leading the first-ever clinical study to use HIV/AIDS medications to prevent HIV-positive pregnant women from passing the virus to their babies. This seminal clinical trial paved the way for current prevention of mother-to-child transmission of HIV (PMTCT) programs that have led to virtual elimination of pediatric HIV infection in the United States and a 58 percent reduction in new pediatric HIV infections worldwide. In 2012 Dr. Mofenson received the prestigious Samuel J. Heyman Service to America Federal Employee of the Year Award for her pivotal role in saving the lives of women and children impacted by HIV and AIDS.
To learn more about EGPAF’s research programs, visit www.pedaids.org/research.
About the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF):
EGPAF is the global leader in the fight against pediatric HIV/ AIDS and has reached 20 million women with services to prevent transmission of HIV to their babies. It currently supports more than 7,000 health facilities and works in 15 countries to implement prevention, care, and treatment services; to further advance innovative research; and to execute global advocacy activities that bring dramatic change to the lives of millions of women, children, and families worldwide. For more information, visit www.pedaids.org.